eResearchTechnology files initial public offering
eResearchTechnology (eRT) has filed for an initial public offering as part of an overall effort to reposition its parent company, Premier Research Worldwide (PRWW), as a provider of Internet clinical
eResearchTechnology (eRT) has filed for an initial public offering as part of an overall effort to reposition its parent company, Premier Research Worldwide (PRWW), as a provider of Internet clinical trials software. Philadelphia-based eRT provides diagnostic services and research capabilities over the Internet to accelerate clinical research trials. Its products are combined into electronic research networks, which connect sponsors, clinical research organizations, physicians, and patients via proprietary database technology and software.
In addition to filing the eRT IPO last month, PRWW recently sold off its clinical research organization, launched eRT, acquired 10% of a Web-hosting company called Medical Advisory Systems, and announced a five-year contract between eRT and MAS whereby MAS will provide application hosting for eRTs products. PRWW will funnel its business offerings through the eRT subsidiary, and essentially act as a holding company. MAS, which is also the ASP for americasdoctor.com on AOL, will use part of the PRWW investment to upgrade its equipment to host eRTs applications and will allow eRT to access MASs 24/7 physician call center as support for several eRT programs, including eSafetyNet and eECG.
© 2000 Miller Freeman, Inc., a United News & Media company.
- Search again
- Homepage
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
